Mandate

Vinge advised Strax on an automatic redemption procedure

Vinge has advised Strax AB in connection with an automatic redemption procedure according to which each outstanding share in Strax has been split into two shares, of which one share (called redemption share) has been redeemed for a proceed of SEK 1.10.

In aggregate, 120,592,332 shares were redeemed at an amount corresponding to approximately SEK 133 million. The redemption procedure was approved by the extraordinary general meeting on 28 December 2018 and the proceeds in the redemption procedure was paid on 30 January 2019.

Vinge’s team consisted mainly of Jesper Schönbeck, Rikard Lindahl, Malte Hedlund, Anna-Karin Alin and Julia Hirschberg. Maria Schultzberg and Henrik Wastenson advised on tax issues.
 

Related

Vinge advises Egetis Therapeutics in connection with ANI Pharmaceuticals’ public cash offer

On 5 November 2026, ANI Pharmaceuticals, Inc., a U.S. biopharmaceutical company listed on The Nasdaq Global Market, announced a recommended public cash offer to the shareholders of Egetis Therapeutics AB (publ) and to the holder of Egetis’ convertible loan and warrants to tender all shares, the convertible loan and the warrants in Egetis to ANI. The total value of the offer amounts to approximately SEK 5,304 million.
November 10, 2026

Vinge has advised Xspray Pharma in connection with its rights issue

Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 90 million before transaction costs, with an over-allotment issue of approximately SEK 72 million.
November 09, 2026

Vinge advises SenzaGen on its acquisition of Alcyomics

SenzaGen AB (publ) has acquired Alcyomics Ltd. The transaction is being financed through a combination of existing cash and a directed issue of convertible bonds.
November 09, 2026